Here’s What Analysts Are Saying About Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the top gene therapy stocks to buy according to hedge funds. Canaccord lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $441 from $411 on February 17 and maintained a Hold rating on the shares, telling investors that it updated its model after the fiscal Q4 results delivered the familiar top and bottom line beat. The firm also stated that Trikafta revenue came in slightly below consensus and Alyftrek slightly above. ...